Pharmacological recanalization therapy in acute ischemic stroke -Evolution, current state and perspectives of intravenous and intra-arterial thrombolysis

Journal of Neuroradiology

Volumn 42, Issue 1, 2015, Pages 30-46

  Hlavica, Martin ^a   Diepers, Michael ^a   Garcia Esperon, Carlos ^a   Ineichen, Benjamin Victor ^b   Nedeltchev, Krassen ^a   Kahles, Timo ^a   Remonda, Luca ^a  

^a CANTONAL HOSPITAL AARAU   (Switzerland)

^b University of Zurich Brain Research Institute   (Switzerland)

Author keywords

Acute ischemic stroke; Alteplase; Intra arterial; Intravenous; RtPA; Thrombolysis

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; DESMOTEPLASE; DUTEPLASE; OCRIPLASMIN; PLACEBO; RETEPLASE; STREPTOKINASE; TENECTEPLASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; FIBRINOLYTIC AGENT;

BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FIBRINOLYTIC THERAPY; FUNCTIONAL ASSESSMENT; HUMAN; INTERMETHOD COMPARISON; MECHANICAL THROMBECTOMY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT DURATION; TREATMENT INDICATION; CEREBROVASCULAR ACCIDENT; ENDOVASCULAR SURGERY; EVIDENCE BASED MEDICINE; FORECASTING; INTERVENTIONAL RADIOLOGY; INTRAARTERIAL DRUG ADMINISTRATION; PROCEDURES; TREATMENT OUTCOME; TRENDS;

ENDOVASCULAR PROCEDURES; EVIDENCE-BASED MEDICINE; FIBRINOLYTIC AGENTS; FORECASTING; HUMANS; INJECTIONS, INTRA-ARTERIAL; RADIOGRAPHY, INTERVENTIONAL; STROKE; THROMBOLYTIC THERAPY; TREATMENT OUTCOME;

EID: 84923608677     PISSN: 01509861     EISSN: 17730406     Source Type: Journal    
DOI: 10.1016/j.neurad.2014.11.004     Document Type: Review

References (140)

1. Koton S., Schneider A.L., Rosamond W.D., et al. Stroke incidence and mortality trends in US communities, 1987 to 2011. JAMA 2014, 312(3):259-268.
2. Rothwell P.M., Coull A.J., Giles M.F., et al. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet 2004, 363(9425):1925-1933.
3. Lozano R., Naghavi M., Foreman K., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380(9859):2095-2128.
4. Murray C.J., Vos T., Lozano R., et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380(9859):2197-2223.
5. Go A.S., Mozaffarian D., Roger V.L., et al. Heart disease and stroke statistics -2014 update: a report from the American Heart Association. Circulation 2014, 129(3):e28-e292.
6. Hacke W., Albers G., Al-Rawi Y., et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005, 36(1):66-73.
7. Sussman B.J., Fitch T.S. Thrombolysis with fibrinolysin in cerebral arterial occlusion. J Am Med Assoc 1958, 167(14):1705-1709.
8. Clarke R.L., Cliffton E.E. The treatment of cerebrovascular thromboses and embolism with fibrinolytic agents. Am J Cardiol 1960, 6:546-551.
9. Meyer J.S., Gilroy J., Barnhart M.I., Johnson J.F. Therapeutic thrombolysis in cerebral thromboembolism. Double-blind evaluation of intravenous plasmin therapy in carotid and middle cerebral arterial occlusion. Neurology 1963, 13:927-937.
10. Meyer J.S., Gilroy J., Barnhart M.I., Johnson J.F. Anticoagulants plus streptokinase therapy in progressive stroke. JAMA 1964, 189:373.
11. Wardlaw J.M., Warlow C.P. Thrombolysis in acute ischemic stroke: does it work?. Stroke 1992, 23(12):1826-1839.
12. Hacke W., Zeumer H., Ferbert A., Brückmann H., del Zoppo G.J. Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease. Stroke 1988, 19(10):1216-1222.
13. Mori E., Yoneda Y., Tabuchi M., et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992, 42(5):976-982.
14. Haley E.C., Brott T.G., Sheppard G.L., et al. Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. Stroke 1993, 24(7):1000-1004.
15. Hacke W., Kaste M., Fieschi C., et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995, 274(13):1017-1025.
16. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995, 333(24):1581-1587.
17. Kwiatkowski T.G., Libman R.B., Frankel M., et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year. N Engl J Med 1999, 340(23):1781-1787.
18. Mokin M., Khalessi A.A., Mocco J., et al. Endovascular treatment of acute ischemic stroke: the end or just the beginning?. Neurosurg Focus 2014, 36(1):E5.
19. Hacke W., Kaste M., Fieschi C., et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998, 352(9136):1245-1251.
20. Brott T.G., Haley E.C., Levy D.E., et al. Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90minutes. Stroke 1992, 23(5):632-640.
21. Haley E.C., Levy D.E., Brott T.G., et al. Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180minutes from onset. Stroke 1992, 23(5):641-645.
22. Marler J.R., Tilley B.C., Lu M., et al. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology 2000, 55(11):1649-1655.
23. Adams H.P., Davis P.H., Leira E.C., et al. Baseline NIH Stroke Scale score strongly predicts outcome after stroke: a report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology 1999, 53(1):126-131.
24. Kwiatkowski T., Libman R., Tilley B.C., et al. The impact of imbalances in baseline stroke severity on outcome in the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study. Ann Emerg Med 2005, 45(4):377-384.
25. Clark W.M., Wissman S., Albers G.W., Jhamandas J.H., Madden K.P., Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999, 282(21):2019-2026.
26. Clark W.M., Albers G.W., Madden K.P., Hamilton S. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Stroke 2000, 31(4):811-816. Thromblytic Therapy in Acute Ischemic Stroke Study Investigators.
27. Hacke W., Donnan G., Fieschi C., et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004, 363(9411):768-774.
28. Hacke W., Kaste M., Bluhmki E., et al. Thrombolysis with alteplase 3 to 4.5hours after acute ischemic stroke. N Engl J Med 2008, 359(13):1317-1329.
29. Davis S.M., Donnan G.A., Parsons M.W., et al. Effects of alteplase beyond 3h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol 2008, 7(4):299-309.
30. Lees K.R., Bluhmki E., von Kummer R., et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010, 375(9727):1695-1703.
31. Jauch E.C., Saver J.L., Adams H.P., et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013, 44(3):870-947.
32. Sandercock P., Wardlaw J.M., Lindley R.I., et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 2012, 379(9834):2352-2363.
33. Wardlaw J.M., Murray V., Berge E., et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 2012, 379(9834):2364-2372.
34. Furlan A.J., Eyding D., Albers G.W., et al. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9hours after stroke onset. Stroke 2006, 37(5):1227-1231.
35. Olivot J.M., Mlynash M., Thijs V.N., et al. Relationships between infarct growth, clinical outcome, and early recanalization in diffusion and perfusion imaging for understanding stroke evolution (DEFUSE). Stroke 2008, 39(8):2257-2263.
36. Lansberg M.G., Thijs V.N., Bammer R., et al. The MRA-DWI mismatch identifies patients with stroke who are likely to benefit from reperfusion. Stroke 2008, 39(9):2491-2496.
37. Hacke W., Furlan A.J., Al-Rawi Y., et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol 2009, 8(2):141-150.
38. Mishra N.K., Albers G.W., Davis S.M., et al. Mismatch-based delayed thrombolysis: a meta-analysis. Stroke 2010, 41(1):e25-e33.
39. Lundbeck A.S. A randomised, double-blind, parallel-group placebo-controlled phase III study to evaluate the efficacy and safety of desmoteplase in subjects with acute ischemic stroke. ClinicalTrials.gov, 2014.
40. Ma H., Parsons M.W., Christensen S., et al. A multicentre, randomized, double-blinded, placebo-controlled Phase III study to investigate EXtending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND). Int J Stroke 2012, 7(1):74-80.
41. Fisher M., Albers G.W. Advanced imaging to extend the therapeutic time window of acute ischemic stroke. Ann Neurol 2013, 73(1):4-9.
42. Götz T. Efficacy and safety of MRI-based thrombolysis in wake-up stroke: a randomised, double-blind, placebo-controlled trial. ClinicalTrials.gov, 2014.
43. Fletcher A.P., Alkjaersig N., Lewis M., et al. A pilot study of urokinase therapy in cerebral infarction. Stroke 1976, 7(2):135-142.
44. Fujishima M., Omae T., Tanaka K., Iino K., Matsuo O., Mihara H. Controlled trial of combined urokinase and dextran sulfate therapy in patients with acute cerebral infarction. Angiology 1986, 37(7):487-498.
45. Haley E.C., Lyden P.D., Johnston K.C., Hemmen T.M. A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke 2005, 36(3):607-612. Investigators TiS.
46. Shaltoni H.M., Albright K.C., Gonzales N.R., et al. Is intra-arterial thrombolysis safe after full-dose intravenous recombinant tissue plasminogen activator for acute ischemic stroke?. Stroke 2007, 38(1):80-84.
47. Donnan G.A., Hommel M., Davis S.M., McNeil J.J. Streptokinase in acute ischaemic stroke. Steering Committees of the ASK and MAST-E trials. Australian Streptokinase Trial. Lancet 1995, 346(8966):56.
48. Multicentre Acute Stroke Trial -Italy (MAST-I) Group Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 1995, 346(8989):1509-1514.
49. Hommel M., Boissel J.P., Cornu C., et al. Termination of trial of streptokinase in severe acute ischaemic stroke. Lancet 1995, 345(8941):57.
50. The Multicenter Acute Stroke Trial -Europe Study Group Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 1996, 335(3):145-150.
51. Ducrocq X., Bracard S., Taillandier L., et al. Comparison of intravenous and intra-arterial urokinase thrombolysis for acute ischaemic stroke. J Neuroradiol 2005, 32(1):26-32.
52. Kalyan N.K., Lee S.G., Wilhelm J., et al. Structure-function analysis with tissue-type plasminogen activator. Effect of deletion of NH2-terminal domains on its biochemical and biological properties. J Biol Chem 1988, 263(8):3971-3978.
53. van Zonneveld A.J., Veerman H., Pannekoek H. Autonomous functions of structural domains on human tissue-type plasminogen activator. Proc Natl Acad Sci U S A 1986, 83(13):4670-4674.
54. Adibhatla R.M., Hatcher J.F. Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies. CNS Neurol Disord Drug Targets 2008, 7(3):243-253.
55. Anderson H.V., Willerson J.T. Thrombolysis in acute myocardial infarction. N Engl J Med 1993, 329(10):703-709.
56. Liao X., Wang Y., Pan Y., et al. Standard-dose intravenous tissue-type plasminogen activator for stroke is better than low doses. Stroke 2014, 45(8):2354-2358.
57. Tanswell P., Modi N., Combs D., Danays T. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Clin Pharmacokinet 2002, 41(15):1229-1245.
58. Bivard A., Lin L., Parsons M.W. Review of stroke thrombolytics. J Stroke 2013, 15(2):90-98.
59. Parsons M.W., Miteff F., Bateman G.A., et al. Acute ischemic stroke: imaging-guided tenecteplase treatment in an extended time window. Neurology 2009, 72(10):915-921.
60. Haley E.C., Thompson J.L., Grotta J.C., et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke 2010, 41(4):707-711.
61. Parsons M., Spratt N., Bivard A., et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med 2012, 366(12):1099-1107.
62. Logallo N., Kvistad C.E., Nacu A., et al. The Norwegian tenecteplase stroke trial (NOR-TEST): randomised controlled trial of tenecteplase vs. alteplase in acute ischaemic stroke. BMC Neurol 2014, 14:106.
63. Hill MD, Coutts SB. A phase 2, prospective, two cohort, dose-escalation, safety and feasibility study of thrombolysis for minor ischemic stroke with proven acute symptomatic occlusion using TNK-tPA. ClinicalTrials.gov, 2014.
64. Muir K. Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis -Pilot phase (ATTEST). ClinicalTrials.gov, 2012.
65. Patel R., Ispoglou S., Apostolakis S. Desmoteplase as a potential treatment for cerebral ischaemia. Expert Opin Investig Drugs 2014, 23(6):865-873.
66. Seet R.C., Rabinstein A.A. Symptomatic intracranial hemorrhage following intravenous thrombolysis for acute ischemic stroke: a critical review of case definitions. Cerebrovasc Dis 2012, 34(2):106-114.
67. Ahmed N., Kellert L., Lees K.R., et al. Results of intravenous thrombolysis within 4.5 to 6hours and updated results within 3 to 4.5hours of onset of acute ischemic stroke recorded in the Safe Implementation of Treatment in Stroke-International Stroke Thrombolysis Register (SITS-ISTR): an observational study. JAMA Neurol 2013, 70(7):837-844.
68. Emberson J., Lees K.R., Lyden P., et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014, 384:1929-1935.
69. The NINDS t-PA Stroke Study Group Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 1997, 28(11):2109-2118.
70. Tanne D., Kasner S.E., Demchuk A.M., et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation 2002, 105(14):1679-1685.
71. Patel S.C., Levine S.R., Tilley B.C., et al. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. JAMA 2001, 286(22):2830-2838.
72. Whiteley W.N., Slot K.B., Fernandes P., Sandercock P., Wardlaw J. Risk factors for intracranial hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator: a systematic review and meta-analysis of 55 studies. Stroke 2012, 43(11):2904-2909.
73. Diedler J., Ahmed N., Sykora M., et al. Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset. Stroke 2010, 41(2):288-294.
74. Committee ESOEE, Committee EW Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008, 25(5):457-507.
75. Miedema I., Luijckx G.J., De Keyser J., Koch M., Uyttenboogaart M. Thrombolytic therapy for ischaemic stroke in patients using warfarin: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2012, 83(5):537-540.
76. Xian Y., Liang L., Smith E.E., et al. Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. JAMA 2012, 307(24):2600-2608.
77. Strbian D., Engelter S., Michel P., et al. Symptomatic intracranial hemorrhage after stroke thrombolysis: the SEDAN score. Ann Neurol 2012, 71(5):634-641.
78. Mazya M., Egido J.A., Ford G.A., et al. Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: Safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score. Stroke 2012, 43(6):1524-1531.
79. Rohan V., Baxa J., Tupy R., et al. Length of occlusion predicts recanalization and outcome after intravenous thrombolysis in middle cerebral artery stroke. Stroke 2014, 45(7):2010-2017.
80. Khalessi A.A., Natarajan S.K., Orion D., et al. Acute stroke intervention. JACC Cardiovasc Interv 2011, 4(3):261-269.
81. Rha J.H., Saver J.L. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke 2007, 38(3):967-973.
82. Broderick J.P., Palesch Y.Y., Demchuk A.M., et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med 2013, 368(10):893-903.
83. del Zoppo G.J., Ferbert A., Otis S., et al. Local intra-arterial fibrinolytic therapy in acute carotid territory stroke. A pilot study. Stroke 1988, 19(3):307-313.
84. del Zoppo G.J., Higashida R.T., Furlan A.J., Pessin M.S., Rowley H.A., Gent M. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke 1998, 29(1):4-11.
85. Gönner F., Remonda L., Mattle H., et al. Local intra-arterial thrombolysis in acute ischemic stroke. Stroke 1998, 29(9):1894-1900.
86. Furlan A., Higashida R., Wechsler L., et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999, 282(21):2003-2011.
87. Arnold M., Schroth G., Nedeltchev K., et al. Intra-arterial thrombolysis in 100 patients with acute stroke due to middle cerebral artery occlusion. Stroke 2002, 33(7):1828-1833.
88. Ogawa A., Mori E., Minematsu K., et al. Randomized trial of intraarterial infusion of urokinase within 6hours of middle cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan. Stroke 2007, 38(10):2633-2639.
89. Arnold M., Nedeltchev K., Mattle H.P., et al. Intra-arterial thrombolysis in 24 consecutive patients with internal carotid artery T occlusions. J Neurol Neurosurg Psychiatry 2003, 74(6):739-742.
90. Lee M., Hong K.S., Saver J.L. Efficacy of intra-arterial fibrinolysis for acute ischemic stroke: meta-analysis of randomized controlled trials. Stroke 2010, 41(5):932-937.
91. Brekenfeld C., Remonda L., Nedeltchev K., et al. Symptomatic intracranial haemorrhage after intra-arterial thrombolysis in acute ischaemic stroke: assessment of 294 patients treated with urokinase. J Neurol Neurosurg Psychiatry 2007, 78(3):280-285.
92. Nedeltchev K., Fischer U., Arnold M., et al. Long-term effect of intra-arterial thrombolysis in stroke. Stroke 2006, 37(12):3002-3007.
93. Arnold M., Koerner U., Remonda L., et al. Comparison of intra-arterial thrombolysis with conventional treatment in patients with acute central retinal artery occlusion. J Neurol Neurosurg Psychiatry 2005, 76(2):196-199.
94. Weber J., Remonda L., Mattle H.P., et al. Selective intra-arterial fibrinolysis of acute central retinal artery occlusion. Stroke 1998, 29(10):2076-2079.
95. Schumacher M., Schmidt D., Jurklies B., et al. Central retinal artery occlusion: local intra-arterial fibrinolysis versus conservative treatment, a multicenter randomized trial. Ophthalmology 2010, 117(7):1367-1375. [e1361].
96. Ciccone A., Valvassori L., Ponzio M., et al. Intra-arterial or intravenous thrombolysis for acute ischemic stroke? The SYNTHESIS pilot trial. J Neurointerv Surg 2010, 2(1):74-79.
97. Ciccone A., Valvassori L. Endovascular treatment for acute ischemic stroke. N Engl J Med 2013, 368(25):2433-2434. Investigators SE.
98. Mattle H.P., Arnold M., Georgiadis D., et al. Comparison of intraarterial and intravenous thrombolysis for ischemic stroke with hyperdense middle cerebral artery sign. Stroke 2008, 39(2):379-383.
99. Mazighi M., Serfaty J.M., Labreuche J., et al. Comparison of intravenous alteplase with a combined intravenous-endovascular approach in patients with stroke and confirmed arterial occlusion (RECANALISE study): a prospective cohort study. Lancet Neurol 2009, 8(9):802-809.
100. Lewandowski C.A., Frankel M., Tomsick T.A., et al. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. Stroke 1999, 30(12):2598-2605.
101. Investigators IS Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study. Stroke 2004, 35(4):904-911.
102. Investigators IIT The Interventional Management of Stroke (IMS) II Study. Stroke 2007, 38(7):2127-2135.
103. Francis C.W. Ultrasound-enhanced thrombolysis. Echocardiography 2001, 18(3):239-246.
104. Lauer C.G., Burge R., Tang D.B., Bass B.G., Gomez E.R., Alving B.M. Effect of ultrasound on tissue-type plasminogen activator-induced thrombolysis. Circulation 1992, 86(4):1257-1264.
105. Kimura M., Iijima S., Kobayashi K., Furuhata H. Evaluation of the thrombolytic effect of tissue-type plasminogen activator with ultrasonic irradiation: in vitro experiment involving assay of the fibrin degradation products from the clot. Biol Pharm Bull 1994, 17(1):126-130.
106. Francis C.W., Blinc A., Lee S., Cox C. Ultrasound accelerates transport of recombinant tissue plasminogen activator into clots. Ultrasound Med Biol 1995, 21(3):419-424.
107. Alexandrov A.V., Molina C.A., Grotta J.C., et al. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med 2004, 351(21):2170-2178.
108. Molina C.A., Ribo M., Rubiera M., et al. Microbubble administration accelerates clot lysis during continuous 2-MHz ultrasound monitoring in stroke patients treated with intravenous tissue plasminogen activator. Stroke 2006, 37(2):425-429.
109. Hennerici M.G., Kern R., Szabo K. Non-pharmacological strategies for the treatment of acute ischaemic stroke. Lancet Neurol 2013, 12(6):572-584.
110. Daffertshofer M., Gass A., Ringleb P., et al. Transcranial low-frequency ultrasound-mediated thrombolysis in brain ischemia: increased risk of hemorrhage with combined ultrasound and tissue plasminogen activator: results of a phase II clinical trial. Stroke 2005, 36(7):1441-1446.
111. Molina C.A., Barreto A.D., Tsivgoulis G., et al. Transcranial ultrasound in clinical sonothrombolysis (TUCSON) trial. Ann Neurol 2009, 66(1):28-38.
112. Saqqur M., Uchino K., Demchuk A.M., et al. Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke. Stroke 2007, 38(3):948-954.
113. Kidwell C.S., Jahan R., Gornbein J., et al. A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med 2013, 368(10):914-923.
114. Saver J. Solitaire™ FR with the intention for thrombectomy as primary endovascular treatment for acute ischemic stroke (SWIFT PRIME) clinical trial. ClinicalTrials.gov, 2014.
115. Mocco J, Khatri P, Zaidat O. The THERAPY trial: the randomized, concurrent controlled trial to assess the penumbra system's safety and effectiveness in the treatment of acute stroke. ClinicalTrials.gov, 2014.
116. Donnan G.A., Davis S.M., Chambers B.R., et al. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. JAMA 1996, 276(12):961-966.
117. Thijs V.N., Peeters A., Vosko M., et al. Randomized, placebo-controlled, dose-ranging clinical trial of intravenous microplasmin in patients with acute ischemic stroke. Stroke 2009, 40(12):3789-3795.
118. Yamaguchi T., Mori E., Minematsu K., et al. Alteplase at 0.6mg/kg for acute ischemic stroke within 3hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke 2006, 37(7):1810-1815.
119. Sairanen T., Strbian D., Soinne L., et al. Intravenous thrombolysis of basilar artery occlusion: predictors of recanalization and outcome. Stroke 2011, 42(8):2175-2179.
120. Lindsberg P.J., Soinne L., Tatlisumak T., et al. Long-term outcome after intravenous thrombolysis of basilar artery occlusion. JAMA 2004, 292(15):1862-1866.
121. Baruah D.B., Dash R.N., Chaudhari M.R., Kadam S.S. Plasminogen activators: a comparison. Vascul Pharmacol 2006, 44(1):1-9.
122. Ouriel K. Comparison of safety and efficacy of the various thrombolytic agents. Rev Cardiovasc Med 2002, 3(Suppl. 2):S17-S24.
123. Koster R.W., Cohen A.F., Kluft C., Kasper F.J., van der Wouw P.A., Weatherley B.C. The pharmacokinetics of recombinant double-chain t-PA (duteplase): effects of bolus injection, infusions, and administration by weight in patients with myocardial infarction. Clin Pharmacol Ther 1991, 50(3):267-277.
124. Goodman S.G., Menon V., Cannon C.P., et al. Acute ST-segment elevation myocardial infarction: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133(6 Suppl.):708S-775S.
125. Weitz J.I., Stewart R.J., Fredenburgh J.C. Mechanism of action of plasminogen activators. Thromb Haemost 1999, 82(2):974-982.
126. Christow S.P., Gulba D.C. Chemistry, pharmacokinetics, and pharmacodynamics of t-PA, TNK, and DSPA alpha 1. Textbook of coronary thrombosis and thrombolysis 1997, 269-282. Kluwer Academic Publishers. R.C. Becker (Ed.).
127. Brott T. Reopening occluded cerebral arteries. Acute stroke treatment 1997, 171-182. Dunitz, Martin. J. Bogousslavsky (Ed.).
128. Sakharov D.V., Barrertt-Bergshoeff M., Hekkenberg R.T., Rijken D.C. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro. Thromb Haemost 1999, 81(4):605-612.
129. Nagai N., Demarsin E., Van Hoef B., et al. Recombinant human microplasmin: production and potential therapeutic properties. J Thromb Haemost 2003, 1(2):307-313.
130. Suzuki Y., Nagai N., Collen D. Comparative effects of microplasmin and tissue-type plasminogen activator (tPA) on cerebral hemorrhage in a middle cerebral artery occlusion model in mice. J Thromb Haemost 2004, 2(9):1617-1621.
131. Zeumer H., Freitag H.J., Zanella F., Thie A., Arning C. Local intra-arterial fibrinolytic therapy in patients with stroke: urokinase versus recombinant tissue plasminogen activator (r-TPA). Neuroradiology 1993, 35(2):159-162.
132. Brandt T., von Kummer R., Müller-Küppers M., Hacke W. Thrombolytic therapy of acute basilar artery occlusion. Variables affecting recanalization and outcome. Stroke 1996, 27(5):875-881.
133. Cross D.T., Moran C.J., Akins P.T., Angtuaco E.E., Diringer M.N. Relationship between clot location and outcome after basilar artery thrombolysis. AJNR Am J Neuroradiol 1997, 18(7):1221-1228.
134. Arnold M., Nedeltchev K., Schroth G., et al. Clinical and radiological predictors of recanalisation and outcome of 40 patients with acute basilar artery occlusion treated with intra-arterial thrombolysis. J Neurol Neurosurg Psychiatry 2004, 75(6):857-862.
135. Macleod M.R., Davis S.M., Mitchell P.J., et al. Results of a multicentre, randomised controlled trial of intra-arterial urokinase in the treatment of acute posterior circulation ischaemic stroke. Cerebrovasc Dis 2005, 20(1):12-17.
136. Schulte-Altedorneburg G., Hamann G.F., Mull M., et al. Outcome of acute vertebrobasilar occlusions treated with intra-arterial fibrinolysis in 180 patients. AJNR Am J Neuroradiol 2006, 27(10):2042-2047.
137. Ribo M., Molina C.A., Jankowitz B., et al. Stentrievers versus other endovascular treatment methods for acute stroke: comparison of procedural results and their relationship to outcomes. J Neurointerv Surg 2014, 6(4):265-269.
138. Higashida R.T., Furlan A.J., Roberts H., et al. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke. Stroke 2003, 34(8):e109-e137.
139. TIMI Study Group The Thrombolysis in Myocardial Infarction (TIMI) trial, phase I, findings. N Engl J Med 1985, 312(14):932-936.
140. Demchuk A.M., Burgin W.S., Christou I., et al. Thrombolysis in brain ischemia (TIBI) transcranial Doppler flow grades predict clinical severity, early recovery, and mortality in patients treated with intravenous tissue plasminogen activator. Stroke 2001, 32(1):89-93.